in
  1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2009). Available at: www.goldCOPD.com.
  2. van Schayck O, Rabe KF, Rudolf M. COPD: the role of primary care in effective diagnosis, treatment and management. Prim Care Resp J. 2003; 12:16. [Full Text]
  3. Ohar JA, Hamilton RF Jr, Zheng S, et al. COPD is associated with a macrophage scavenger receptor-1 gene sequence variation. Chest. 2010; 137:1098. [Abstract]
  4. American Thoracic Society/European Respiratory Society. Standards for the diagnosis and management of patients with COPD. Available at: http://www.thoracic.org/statements/resources/respiratory-disease-adults/copdexecsum.pdf
  5. Wilt TJ, Niewoehner D, MacDonald R, et al. Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann Intern Med. 2007; 147:639. [Abstract]
  6. Ram FS, Jones PW, Castro AA, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; CD003902. [Abstract]
  7. Murciano D, Auclair MH, Pariente R, Aubier M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989; 320:1521. [Abstract]
  8. Martin RJ, Pak J. Overnight theophylline concentrations and effects on sleep and lung function in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1992; 145:540. [Abstract]
  9. Hanania NA, Sharafkhaneh A, Barber R, Dickey BF. Beta-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med. 2002; 165:1353. [Full text]
  10. Lötvall J. Pharmacology of bronchodilators used in the treatment of COPD. Respir Med. 2000; 94(Suppl E):S6.
  11. Campbell M, Eliraz A, Johansson G, et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med. 2005; 99:1511. [Abstract]
  12. Ohar JA, Donohue FJ. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin Respir Crit Care Med. 2010; 31:321. [Abstract]
  13. Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest. 2008; 133:1079. [Full text]
  14. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA. 2003; 290:2301. [Full text]
  15. Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12-month study. Thorax. 2006; 61:122. [Full text]
  16. Saito Y, Azuma A, Morimoto T, et al. Tiotropium ameliorates symptoms in patients with chronic airway mucus hypersecretion which is resistant to macrolide therapy. Intern Med. 2008; 47:585. [Full text]
  17. Casarosa P, Bouyssou T, Germeyer S, et al. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther. 2009; 330:660. [Full text]
  18. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002; 19:217. [Full text]
  19. O’Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J. 2004; 24:86. [Full text]
  20. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J. 2002; 19:209. [Full text]
  21. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002; 122:47. [Full text]
  22. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005; 143:317. [Full text]
  23. Vogelmeier C, Hederer B, Glaab T et al; POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011; 364:1093. [Abstract]
  24. Barr RG, Bourbeau J, Camargo CA, Ram FSF. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2006; 61:854. [Full text]
  25. Ferguson GT. Why does the lung hyperinflate? Proc Am Thorac Soc. 2006; 3:176. [Full text]
  26. Leith DE, Brown R. Human lung volumes and the mechanisms that set them. Eur Respir J. 1999; 13:468. [Full text]
  27. O’Donnell DE, Laveneziana P. Physiology and consequences of lung hyperinflation in COPD. Eur Respir Rev. 2006; 15:61. [Full text]
  28. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in COPD. N Engl J Med. 2000; 324:1960. [Full text]
  29. Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in mild-to-moderate COPD: A randomized controlled trial. Chest 2011; 139:591. [Abstract]
  30. Barnes NC, Qiu YS, Pavord ID, et al; SCO30005 Study Group. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med. 2006; 173:736. [Full text]
  31. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 361:449. [Abstract]
  32. Johnson M. Corticosteroids: potential beta2-agonist and anticholinergic interactions in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2:320. [Full text]
  33. Aaron SD, Vandemheen KL, Fergusson D, et al; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007; 146:545. [Full text]
  34. Lee TA, Wilke C, Joo M, et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2009; 169:1403. [Full text]
  35. Centers for Disease Control. What adults with chronic obstructive pulmonary disease (COPD) should know about 2009 H1N1 flu (formerly called swine flu). Available at: http://www.cdc.gov/h1n1flu/guidance/copd.htm
  36. Self TH, Chafin CC, Soberman JE. Effect of disease states on theophylline serum concentrations: are we still vigilant? Am J Med Sci. 2000; 319:177. [Abstract]
  37. Timms RM, Khaja FU, Williams GW; Nocturnal Oxygen Therapy Trial Group. Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med. 1985; 102:29. [Abstract]
  38. Uniphyl Tablets (theophylline). Package insert. Stamford, CT: Purdue Pharma; 2010.
  39. Schols AM, Wesseling G, Kester AD, et al. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J. 2001; 17:337. [Full text]
  40. Garrod R, Paul EA, Wedzicha JA. Supplemental oxygen during pulmonary rehabilitation in patients with COPD with exercise hypoxaemia. Thorax. 2000; 55:539. [Full text]
  41. Crockett AJ, Cranston JM, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005; CD001744. [Abstract]
  42. O’Donnell DE, Bain DJ, Webb KA. Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation. Am J Respir Crit Care Med. 1997; 155:530. [Abstract]
Copyright © 2010, 2011  Perelman School of Medicine at the University of Pennsylvania Office of Continuing Medical Education & BestPractice CPD, LLC®. All rights reserved.